Skip to main content

Advertisement

Table 1 Comparison of clinical manifestations and laboratory features between H19low and H19high AML patients

From: H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia

Patient’s parameters Low (n = 82) High (n = 79) P value
Sex, male/female 44/38 54/25 0.075
Median age, years (range) 51.5 (10–87) 61 (17–93) 0.009
Median WBC, × 109/L (range) 7.7 (1.0–185.4) 31.1 (0.3–528.0) 0.004
Median hemoglobin, g/L (range) 75 (40–133) 78.5 (32–144) 0.144
Median platelets, × 109/L (range) 42 (5–447) 33 (3–399) 0.262
Median BM blasts, % (range) 44 (3.0–94.5) 43 (1–99) 0.339
Karyotype classification 0.010
 Favorable 29 (35%) 14 (18%)  
 Intermediate 37 (45%) 55 (70%)  
 Poor 12 (15%) 9 (11%)  
 No data 4 (5%) 1 (1%)  
Karyotype 0.048
 Normal 28 (34%) 42 (54%)  
 t(8;21) 7 (9%) 5 (6%)  
 t(16;16) 0 (0%) 1 (1%)  
 t(15;17) 22 (27%) 8 (10%)  
 t(9;22) 0 (0%) 1 (1%)  
 + 8 3 (4%) 4 (5%)  
 − 5/5q− 1 (1%) 2 (3%)  
 − 7/7q− 1 (1%) 0 (0%)  
 Complex 10 (12%) 6 (8%)  
 Others 6 (7%) 9 (11%)  
 No data 4 (5%) 1 (1%)  
Gene mutation
CEBPA (+/−) 10/66 7/61 0.617
NPM1 (+/−) 6/70 11/57 0.195
FLT3-ITD (+/−) 6/70 13/55 0.053
c-KIT (+/−) 4/72 1/67 0.370
N/K-RAS (+/−) 4/72 8/60 0.228
IDH1/2 (+/−) 2/74 6/62 0.149
DNMT3A (+/−) 2/74 9/59 0.025
U2AF1 (+/−) 3/73 3/65 1.000
SRSF2 (+/−) 3/75 4/66 0.708
SETBP1 (+/−) 1/77 1/69 1.000
CR (+/−) 40/35 22/52 0.005
  1. AML acute myeloid leukemia, WBC white blood cells, CR complete remission